68. Bioorg Med Chem. 2018 May 1;26(8):1638-1642. doi: 10.1016/j.bmc.2018.02.010. Epub2018 Feb 9.Design and synthesis of estrogen receptor ligands with a4-heterocycle-4-phenylheptane skeleton.Eto R(1), Misawa T(2), Noguchi-Yachide T(3), Ohoka N(4), Kurihara M(5), NaitoM(4), Tanaka M(1), Demizu Y(6).Author information: (1)Graduate School of Biomedical Sciences, Nagasaki University, 1-14Bunkyo-machi, Nagasaki 852-8521, Japan.(2)Division of Organic Chemistry, National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-9501, Japan. Electronicaddress: misawa@nihs.go.jp.(3)Institute of Molecular & Cellular Biology, The University of Tokyo, 1-1-1Yayoi, Bunkyo-ku, Tokyo 113-0032, Japan.(4)Division of Molecular Target and Gene Therapy Products, National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-9501,Japan.(5)Department of Pharmaceutical Sciences, International University of Health and Welfare, 2600-1 Kitakanemaru, Ohtawara City, Tochigi 324-8501, Japan.(6)Division of Organic Chemistry, National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-9501, Japan. Electronicaddress: demizu@nihs.go.jp.The estrogen receptor (ER), a member of the nuclear receptor (NR) family, isinvolved in the regulation of physiological effects such as reproduction and bonehomeostasis. Approximately 70% of human breast cancers are hormone-dependent and ERα-positive, and, thus, ER antagonists are broadly used in breast cancertherapy. We herein designed and synthesized a set of ER antagonists with a4-heterocycle-4-phenylheptane skeleton.Copyright © 2018 Elsevier Ltd. All rights reserved.DOI: 10.1016/j.bmc.2018.02.010 PMID: 29525335 